8-K: Bionano Genomics Reports Mixed Q2 Results with Revenue Decline but Increased OGM System Installs

Bionano Genomics reported a 10% decrease in revenue for Q2 2024 compared to Q2 2023, but saw a 29% increase in the installed base of its optical genome mapping (OGM) systems.

Summary

• Bionano Genomics announced its financial results for the second quarter of 2024, showing a mixed performance.
• Revenue for Q2 2024 was $7.8 million, a 10% decrease compared to $8.7 million in Q2 2023.
• The company's installed base of optical genome mapping (OGM) systems grew by 29% year-over-year, reaching 363 systems.
• However, the number of nanochannel array flowcells sold decreased by 13% to 6,165 in Q2 2024.
• Bionano achieved a new Category I CPT code for OGM, which is expected to improve reimbursement for their OGM-Dx HemeOne test.
• The company completed a registered direct offering and private placement, raising $10 million upfront and potentially an additional $20 million.
• Bionano retired $15.3 million of convertible notes with a $17.6 million redemption payment and a $2.2 million retirement fee.
• GAAP gross margin improved to 33% in Q2 2024 from 27% in Q2 2023, while non-GAAP gross margin was 35% compared to 29% in the same period.
• GAAP operating expenses decreased by 53% year-over-year to $19.6 million, and non-GAAP operating expenses decreased by 46% to $18.8 million.
• The company's cash, cash equivalents, and available-for-sale securities totaled $30.3 million as of June 30, 2024.
• Bionano reaffirmed its full-year 2024 revenue guidance of $36 to $40 million and expects Q3 2024 revenue to be between $7.9 and $8.9 million.
• The company anticipates reducing annualized non-GAAP operating expenses by approximately $65 to $75 million by the first quarter of 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive developments like increased OGM installations and cost reductions, but these are offset by revenue decline and a decrease in flowcell sales. The company's financial position remains a concern, leading to a neutral sentiment.

Positives

• The installed base of OGM systems increased by 29% year-over-year, indicating growing adoption of the technology.
• The establishment of a new Category I CPT code for OGM is a significant step towards reimbursement and wider clinical adoption.
• The company successfully raised $10 million in upfront capital and has the potential to raise an additional $20 million.
• Bionano improved its gross margin, with GAAP gross margin increasing to 33% and non-GAAP gross margin reaching 35%.
• Operating expenses decreased significantly, with GAAP operating expenses down 53% and non-GAAP operating expenses down 46%.
• The company is on track to reduce annualized non-GAAP operating expenses by $65 to $75 million by Q1 2025.
• Key publications support OGM's utility in prenatal and cancer applications, highlighting its accuracy and potential for improved diagnostics.

Negatives

• Revenue decreased by 10% in Q2 2024 compared to Q2 2023, indicating a slowdown in sales.
• The number of nanochannel array flowcells sold decreased by 13%, suggesting a potential decrease in utilization of existing systems.
• The company incurred a significant cost of $19.8 million to retire $15.3 million of convertible notes.
• Cash, cash equivalents, and available-for-sale securities decreased to $30.3 million as of June 30, 2024, from $140.1 million at the end of 2023.

Risks

• The company faces risks associated with adverse geopolitical and macroeconomic events, such as bank failures and the ongoing conflicts in Ukraine and the Middle East.
• There are challenges inherent in developing, manufacturing, and commercializing products, which could impact future growth.
• Bionano's ability to obtain sufficient financing to fund its strategic plans and commercialization efforts is a risk.
• The company's ability to drive adoption of OGM and its technology solutions is subject to market conditions and competition.
• The company's ability to achieve the expected reduction in annualized operating expenses is not guaranteed.
• The company's ability to obtain stockholder approval for the exercise of the Series A and Series B warrants is not guaranteed.

Future Outlook

Bionano expects full-year 2024 revenue to be between $36 and $40 million and Q3 2024 revenue to be between $7.9 and $8.9 million. The company also anticipates reducing annualized non-GAAP operating expenses by approximately $65 to $75 million by the first quarter of 2025.

Management Comments

• Erik Holmlin, PhD, president and chief executive officer of Bionano, stated that they saw positive growth in the OGM installed base and key advancements to their VIA software.
• Erik Holmlin also mentioned the achievement of a significant milestone with the establishment of a Category I CPT code for OGM.
• Glsen Kama, chief financial officer at Bionano, noted significant year-over-year improvements in operating expense and cash burn due to cost savings initiatives.

Industry Context

The establishment of a new CPT code for OGM is a positive development for the genomics industry, potentially increasing adoption and reimbursement for Bionano's technology. The company's focus on cost reduction and efficiency aligns with broader trends in the biotech sector, where companies are seeking to optimize operations and extend their cash runway.

Comparison to Industry Standards

• Bionano's revenue decline of 10% contrasts with some other genomics companies that have shown growth in the same period, such as Illumina, which reported a 1% increase in revenue in their most recent quarter.
• The 29% increase in OGM system installations is a positive sign, but the 13% decrease in flowcell sales suggests that utilization of the installed base may be a challenge.
• The improvement in gross margin to 33% is a positive trend, but it still lags behind some of the more established players in the industry, such as Thermo Fisher Scientific, which reported a gross margin of 40.5% in their most recent quarter.
• The reduction in operating expenses is a significant achievement, but the company's cash position remains a concern, especially when compared to companies with more robust balance sheets, such as Agilent Technologies.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline but encouraged by the increase in OGM system installations and cost reductions.
• Employees may be impacted by the ongoing cost-saving initiatives and restructuring efforts.
• Customers may benefit from the new CPT code and the anticipated improvements to the company's workflow and software.
• Suppliers may be affected by the company's efforts to reduce expenses and streamline operations.
• Creditors may be concerned about the company's cash position and debt levels.

Next Steps

• Bionano plans to continue investing in opportunities to increase global adoption and utilization of OGM.
• The company anticipates a full commercial launch of the Ionic Purification System in the fourth quarter of 2024.
• Improvements to data analysis processing time on the Stratys Compute are expected in the fourth quarter of 2024.
• Bionano will continue to focus on strengthening the company's long-term growth profile and prioritizing efficiencies.

Key Dates

Keywords

Optical Genome Mapping, OGM, Genomics, Cytogenomics, CPT Code, Revenue, Gross Margin, Operating Expenses, Flowcells, Bionano Genomics, Financial Results, Installed Base, Molecular Diagnostics